US Bancorp’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.1M Sell
262,178
-6,680
-2% -$1M 0.04% 225
2026
Q1
$41.1M Buy
268,858
+1,589
+0.6% +$244K 0.05% 221
2025
Q4
$36.8M Buy
267,269
+13,012
+5% +$1.7M 0.04% 234
2025
Q3
$32.6M Buy
254,257
+31,197
+14% +$3.81M 0.04% 258
2025
Q2
$27M Sell
223,060
-22,670
-9% -$2.56M 0.03% 277
2025
Q1
$27.4M Sell
245,730
-2,810
-1% -$299K 0.04% 272
2024
Q4
$24.2M Buy
248,540
+5,913
+2% +$631K 0.03% 285
2024
Q3
$27.9M Buy
242,627
+26,150
+12% +$2.97M 0.04% 270
2024
Q2
$23M Sell
216,477
-47,599
-18% -$4.78M 0.03% 278
2024
Q1
$25.5M Sell
264,076
-2,467
-0.9% -$253K 0.04% 275
2023
Q4
$26.9M Buy
266,543
+31,452
+13% +$3.04M 0.04% 259
2023
Q3
$23.9M Buy
235,091
+26,946
+13% +$2.74M 0.04% 267
2023
Q2
$21M Buy
208,145
+3,527
+2% +$353K 0.03% 286
2023
Q1
$18.8M Sell
204,618
-27,261
-12% -$2.38M 0.03% 293
2022
Q4
$21M Buy
231,879
+40,537
+21% +$3.41M 0.04% 278
2022
Q3
$14.5M Sell
191,342
-66,954
-26% -$5.55M 0.03% 302
2022
Q2
$21.8M Buy
258,296
+21,434
+9% +$1.88M 0.04% 251
2022
Q1
$20.8M Sell
236,862
-10,510
-4% -$910K 0.03% 290
2021
Q4
$21.6M Sell
247,372
-56,933
-19% -$4.73M 0.03% 288
2021
Q3
$24.9M Sell
304,305
-19,316
-6% -$1.74M 0.05% 250
2021
Q2
$29.5M Buy
323,621
+19,444
+6% +$1.73M 0.06% 228
2021
Q1
$26M Buy
304,177
+8,606
+3% +$772K 0.05% 242
2020
Q4
$27.9M Buy
295,571
+7,536
+3% +$659K 0.06% 223
2020
Q3
$25M Sell
288,035
-27,503
-9% -$2.38M 0.06% 229
2020
Q2
$27.6M Sell
315,538
-5,505
-2% -$475K 0.07% 203
2020
Q1
$26.5M Buy
321,043
+78,210
+32% +$6.98M 0.08% 192
2019
Q4
$23M Buy
242,833
+4,910
+2% +$441K 0.06% 234
2019
Q3
$20.7M Buy
237,923
+41,876
+21% +$3.76M 0.06% 249
2019
Q2
$17.9M Sell
196,047
-57,170
-23% -$4.84M 0.05% 274
2019
Q1
$21.8M Sell
253,217
-74,807
-23% -$6.01M 0.06% 235
2018
Q4
$25.2M Buy
328,024
+50,705
+18% +$3.95M 0.08% 197
2018
Q3
$21.4M Buy
277,319
+32,196
+13% +$2.38M 0.06% 235
2018
Q2
$16.6M Buy
245,123
+13,402
+6% +$925K 0.05% 270
2018
Q1
$16.8M Sell
231,721
-36,131
-13% -$2.75M 0.05% 265
2017
Q4
$20.2M Buy
267,852
+23,188
+9% +$1.75M 0.06% 241
2017
Q3
$18.8M Sell
244,664
-7,060
-3% -$533K 0.06% 247
2017
Q2
$18.8M Sell
251,724
-98,034
-28% -$6.95M 0.06% 242
2017
Q1
$23.3M Sell
349,758
-9,286
-3% -$619K 0.08% 202
2016
Q4
$23.4M Buy
359,044
+28,689
+9% +$1.86M 0.08% 193
2016
Q3
$23.4M Buy
330,355
+47,465
+17% +$3.46M 0.09% 196
2016
Q2
$20.9M Sell
282,890
-31,330
-10% -$2.16M 0.08% 204
2016
Q1
$20.4M Sell
314,220
-61,061
-16% -$4.15M 0.08% 206
2015
Q4
$28.9M Sell
375,281
-17,574
-4% -$1.4M 0.12% 161
2015
Q3
$32.4M Sell
392,855
-9,725
-2% -$866K 0.14% 147
2015
Q2
$35.5M Buy
402,580
+3,911
+1% +$359K 0.14% 146
2015
Q1
$35.2M Sell
398,669
-7,555
-2% -$670K 0.14% 142
2014
Q4
$33.7M Buy
406,224
+29,584
+8% +$2.45M 0.13% 145
2014
Q3
$31.8M Buy
376,640
+29,234
+8% +$2.37M 0.13% 143
2014
Q2
$28.2M Buy
347,406
+24,102
+7% +$1.9M 0.11% 161
2014
Q1
$24.6M Buy
323,304
+9,784
+3% +$713K 0.1% 171
2013
Q4
$22.6M Buy
313,520
+16,721
+6% +$1.16M 0.09% 178
2013
Q3
$20.4M Sell
296,799
-11,194
-4% -$741K 0.09% 172
2013
Q2
$19.5M Buy
+307,993
New +$20M 0.09% 174

Other funds holding NVS

US Bancorp's NVS Position: Q2 2026 in Review

US Bancorp reduced its Novartis (NVS) stake by 2.5% in Q2 2026, selling an estimated $1M and leaving 262,178 shares worth $41.1M. The position accounts for 0.04% of the portfolio, ranked #225.

US Bancorp first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • US Bancorp held 262,178 shares of Novartis worth $41.1M as of Q2 2026.
  • US Bancorp sold 6,680 Novartis shares in Q2 2026, an estimated $1M.
  • Novartis made up 0.04% of US Bancorp's portfolio in Q2 2026, its #225 holding.
  • US Bancorp first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.